The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
L‐asparaginase treatment in acute lymphoblastic leukemia: A focus on Erwinia asparaginase
Open accessAbstract
Asparaginases are a cornerstone of treatment protocols for acute lymphoblastic leukemia (ALL) and are used for remission induction and intensification treatment in all pediatric regimens and in the majority of adult treatment protocols. Extensive clinical data have shown that intensive asparaginase treatment improves clinical outcomes in childhood ALL. Three asparaginase preparations are available: the native asparaginase derived from Escherichia coli (E. coli asparaginase), a pegylated form of this enzyme (PEG-asparaginase), and a product isolated from Erwinia chrysanthemi, ie, Erwinia asparaginase. Clinical hypersensitivity reactions and silent inactivation due to antibodies against E. coli asparaginase, lead to inactivation of E. coli asparaginase in up to 60% of cases. Current treatment protocols include E. coli asparaginase or PEG-asparaginase for first-line treatment of ALL. Typically, patients exhibiting sensitivity to one formulation of asparaginase are switched to another to ensure they receive the most efficacious treatment regimen possible. Erwinia asparaginase is used as a second- or third-line treatment in European and US protocols. Despite the universal inclusion of asparaginase in such treatment protocols, debate on the optimal formulation and dosage of these agents continues. This article provides an overview of available evidence for optimal use of Erwinia asparaginase in the treatment of ALL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Depletion of plasma asparagine by a recombinant form of bacterial L-Asparaginase is an effective anticancer intervention for this cancer type (Hill et al., 1967; Pieters et al., 2011).”
From The emerging hallmarks of cancer metabolism (2016) · cites this paper as Pieters et al., 2011
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Summary of product characteristics
(2013) · Pharmaceutical Medicine · doi:10.1093/med/9780199609147.003.0027 · Cited by 1,918
Pui, C.-H., Robison, L. L., & Look, A. T. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60457-2 · Cited by 1,564
Self-citationTreating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation
Pui, C.-H., Campana, D., Pei, D., Bowman, W. P., Sandlund, J. T., Kaste, S. C., Ribeiro, R. C., Rubnitz, J. E., Raimondi, S. C., Onciu, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900386 · Cited by 1,215
Self-citationSilverman, L. B. (2001) · Blood · doi:10.1182/blood.v97.5.1211 · Cited by 869
Self-citationArmstrong, J. K., Hempel, G., Koling, S., Chan, L. S., Fisher, T., Meiselman, H. J., & Garratty, G. (2007) · Cancer · doi:10.1002/cncr.22739 · Cited by 699
Kantarjian, H. M., Thomas, D. A., O'Brien, S. M., Cortes, J. E., Giles, F. J., Jeha, S., Bueso-Ramos, C., Pierce, S. A., Shan, J., Koller, C. A., et al. (2004) · Cancer · doi:10.1002/cncr.20668 · Cited by 638
Möricke, A., Reiter, A., Zimmermann, M., Gadner, H., Stanulla, M., Dördelmann, M., Löning, L., Beier, R., Ludwig, W.-D., Ratei, R., et al. (2008) · Blood · doi:10.1182/blood-2007-09-112920 · Cited by 611
Self-citationBoissel, N., Auclerc, M.-F., Lhéritier, V., Pérel, Y., Thomas, X., Leblanc, T. M., Rousselot, P. H., Cayuela, J., Gabert, J. A., Fegueux, N., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.053 · Cited by 606
Self-citationAvramis, V. I., Sencer, S., Periclou, A. P., Sather, H. N., Bostrom, B., Cohen, L. J., Ettinger, A. G., Ettinger, L. J., Franklin, J. L., Gaynon, P. S., et al. (2002) · Blood · doi:10.1182/blood.v99.6.1986 · Cited by 492
Pui, C., Sandlund, J. T., Pei, D., Campana, D., Rivera, G. K., Ribeiro, R. C., Rubnitz, J. E., Razzouk, B. I., Howard, S. C., Hudson, M. M., et al. (2004) · Blood · doi:10.1182/blood-2004-04-1616 · Cited by 461
Self-citationClavell, L. A., Gelber, R. D., Cohen, H. J., Hitchcock‐Bryan, S., Cassady, J. R., Tarbell, N. J., Blattner, S. R., Tantravahi, R. V., Leavitt, P., & Sallan, S. E. (1986) · New England Journal of Medicine · doi:10.1056/nejm198609113151101 · Cited by 417
Duval, M. (2002) · Blood · doi:10.1182/blood.v99.8.2734 · Cited by 409
Moghrabi, A., Levy, D. E., Asselin, B. L., Barr, R. D., Clavell, L. A., Hurwitz, C. A., Samson, Y., Schorin, M. A., Dalton, V. K., Lipshultz, S. E., et al. (2006) · Blood · doi:10.1182/blood-2006-06-027714 · Cited by 399
Self-citationAmylon, M. D., Shuster, J. J., Pullen, J., Berard, C. W., Link, M., Wharam, M. D., Katz, J., Yu, A. L.-T., Laver, J. H., Ravindranath, Y., et al. (1999) · Leukemia · doi:10.1038/sj.leu.2401310 · Cited by 346
Dinndorf, P. A., Gootenberg, J. E., Cohen, M. H., Keegan, P., & Pazdur, R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-8-991 · Cited by 326
de Bont, J. M., van der Holt, B., Dekker, A. W., den Berg, A. V. D. D.-V., Sonneveld, P., & Pieters, R. (2004) · Leukemia · doi:10.1038/sj.leu.2403538 · Cited by 322
Self-citationRamanujachar, R., Richards, S. M., Hann, I. M., Goldstone, A. H., Mitchell, C., Vora, A. J., Rowe, J. M., & Webb, D. K. H. (2006) · Pediatric Blood & Cancer · doi:10.1002/pbc.20749 · Cited by 256
Huguet, F., Girard, N., Guerche, C. S.-E., Hennequin, C., Mornex, F., & Azria, D. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.7921 · Cited by 236
Panosyan, E. H., Seibel, N. L., Martín‐Aragón, S., Gaynon, P. S., Avramis, I. A., Sather, H. N., Franklin, J. L., Nachman, J. B., Ettinger, L. J., La, M., et al. (2004) · Journal of Pediatric Hematology/Oncology · doi:10.1097/00043426-200404000-00002 · Cited by 236
Boos, J., Werber, G., Ahlke, E., Schulze-Westhoff, P., Nowak‐Göttl, U., Würthwein, G., Verspohl, E. J., Ritter, J., & Jürgens, H. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(96)00131-1 · Cited by 218
Self-citationMaunsell, E., Brisson, J., & Deschěnes, L. (1992) · Cancer · doi:10.1002/1097-0142(19920701)70:1 · Cited by 208
Pession, A., Valsecchi, M. G., Masera, G., Kamps, W. A., Magyarosy, E., Rizzari, C., van Wering, E. R., Nigro, L. L., van der Does, A., Locatelli, F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.411 · Cited by 203
Self-citationSallan, S. E., Hitchcock‐Bryan, S., Gelber, R. D., Cassady, J. R., Frei, E., & Nathan, D. (1983) · PubMed · Cited by 201
Intensified and Shortened Cyclical Chemotherapy for Adult Acute Lymphoblastic Leukemia
LINKER, C. A., Damon, L. E., Ries, C. A., & Navarro, W. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.116 · Cited by 199
Barry, E. V., DeAngelo, D. J., Neuberg, D. S., Stevenson, K. E., Loh, M. L., Asselin, B. L., Barr, R. D., Clavell, L. A., Hurwitz, C. A., Moghrabi, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.6397 · Cited by 190
Self-citationWoo, M. H., Hak, L. J., Storm, M. C., Sandlund, J. T., Ribeiro, R. C., Rivera, G. K., Rubnitz, J. E., Harrison, P. L., Wang, B., Evans, W. E., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.7.1525 · Cited by 182
Self-citationAsparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia.
Avramis, V. I., & Tiwari, P. (2006) · PubMed Central · Cited by 177
Kearney, S. L., Dahlberg, S. E., Levy, D. E., Voss, S. D., Sallan, S. E., & Silverman, L. B. (2009) · Pediatric Blood & Cancer · doi:10.1002/pbc.22076 · Cited by 170
Self-citationSilverman, L. B., Declerck, L., Gelber, R. D., Dalton, V. K., Asselin, B., Barr, R., Clavell, L., Hurwitz, C., Moghrabi, A., Samson, Y., et al. (2000) · Leukemia · doi:10.1038/sj.leu.2401980 · Cited by 166
Self-citationAsparaginase-Associated Lipid Abnormalities in Children With Acute Lymphoblastic Leukemia
Parsons, S. K., Skapek, S. X., Neufeld, E. J., Kuhlman, C., Young, M. L., Donnelly, M., Brunzell, J. D., Otvos, J. D., Sallan, S. E., & Rifai, N. (1997) · Blood · doi:10.1182/blood.v89.6.1886 · Cited by 164
Vrooman, L. M., Supko, J. G., Neuberg, D. S., Asselin, B. L., Athale, U. H., Clavell, L. A., Kelly, K. M., Laverdière, C., Michon, B., Schorin, M. A., et al. (2009) · Pediatric Blood & Cancer · doi:10.1002/pbc.22225 · Cited by 162
Self-citationAsselin, B. L. (1999) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-4811-9_69 · Cited by 142
Ollenschläger, G., Roth, E., Linkesch, W., JANSEN, S., Simmel, A., & Mödder, B. (1988) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1988.tb01049.x · Cited by 134
The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia.
Asselin, B. L. (1999) · PubMed · Cited by 129
Ertel, I. J., Nesbit, M. E., Hammond, D., Weiner, J. M., & Sather, H. N. (1979) · PubMed · Cited by 126
Wang, B., Relling, M. V., Storm, M., Woo, M. H., Ribeiro, R. C., Pui, C.-H., & Hak, L. J. (2003) · Leukemia · doi:10.1038/sj.leu.2403011 · Cited by 124
Self-citationAhlke, E., ̈TTL, U. N., Schulze-Westhoff, P., WERBER, G., ̈RSTE, H. B., Würthwein, G., ̈RGENS, H. J., & Boos, J. (1997) · British Journal of Haematology · doi:10.1046/j.1365-2141.1997.d01-2089.x · Cited by 117
Self-citationAppel, I. M., Kazemier, K. M., Boos, J., Lanvers, C., Huijmans, J. G. N., Veerman, A. J. P., van Wering, E., den Boer, M. L., & Pieters, R. (2008) · Leukemia · doi:10.1038/leu.2008.165 · Cited by 116
Self-citationRizzari, C., Zucchetti, M., Conter, V., Diomede, L., Bruno, A., Gavazzi, L. M., Paganini, M., Sparano, P., Nigro, L. L., Aricò, M., et al. (2000) · Annals of Oncology · doi:10.1023/a:1008368916800 · Cited by 112
Self-citationHawkins, D. S., Park, J. R., Thomson, B. G., Felgenhauer, J. L., Holcenberg, J. S., Panosyan, E. H., & Avramis, V. I. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0222 · Cited by 110
Biology and Treatment of Acute Lymphoblastic Leukemia
Pieters, R., & Carroll, W. L. (2008) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2007.11.002 · Cited by 105
Self-citationSchiffer, C. A. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.116 · Cited by 100
Fu, C. H., & Sakamoto, K. M. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.12.1977 · Cited by 94
Zalewska‐Szewczyk, B., Andrzejewski, W., Mlynarski, W. M., Jędrychowska-Dańska, K., Witas, H. W., & Bodalski, J. (2007) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190701292049 · Cited by 88
Nesbit, M., Chard, R. L., Evans, A., Karon, M., & Hammond, G. D. (1979) · PubMed · Cited by 88
Pieters, R., Appel, I. M., Kuehnel, H. J., Tetzlaff-Fohr, I., Pichlmeier, U., van der Vaart, I., Visser, E. G., & Stigter, R. L. (2008) · Blood · doi:10.1182/blood-2008-04-149443 · Cited by 85
Self-citationPegaspargase-induced pancreatitis
Alvarez, O. A., & Zimmerman, G. J. (2000) · Medical and Pediatric Oncology · doi:10.1002/(sici)1096-911x(200003)34:3 · Cited by 85
Amino acid levels following L-asparagine amidohydrolase (EC.3.5.1.1) therapy.
Miller, H. K., Salser, J. S., & Balis, M. E. (1969) · PubMed · Cited by 84
Rizzari, C., Citterio, M., Zucchetti, M., Conter, V., Chiesa, R., Colombini, A., Malguzzi, S., Silvestri, D., & D’Incalci, M. (2006) · PubMed · Cited by 83
Self-citationThe cross-reactivity of anti-asparaginase antibodies against different l-asparaginase preparations
Zalewska‐Szewczyk, B., Gach, A., Wyka, K., Bodalski, J., & Mlynarski, W. M. (2009) · Clinical and Experimental Medicine · doi:10.1007/s10238-008-0026-9 · Cited by 83
Larson, R. A., Fretzin, M., Dodge, R., & Schiffer, C. (1998) · Leukemia · doi:10.1038/sj.leu.2401007 · Cited by 83
Eden, O. B., Shaw, M. P., Lilleyman, J. S., & Richards, S. M. (1990) · Medical and Pediatric Oncology · doi:10.1002/mpo.2950180612 · Cited by 80
Hak, L. J., Relling, M. V., Chen, C., Pei, D., Wang, B., Jt, S., Rubnitz, J. E., & Pui, C. (2004) · Leukemia · doi:10.1038/sj.leu.2403351 · Cited by 67
Self-citationPinheiro, J. P. V., Ahlke, E., Nowak‐Göttl, U., Hempel, G., Müller, H.-J., Lümkemann, K., Schrappe, M., Rath, B., Fleischhack, G., Mann, G. B., et al. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01192.x · Cited by 63
Self-citationL-Asparaginase: discovery and development as a tumor-inhibitory agent.
Broome, J. D. (1981) · PubMed · Cited by 60
Albertsen, B. K., Schrøder, H. D., Ingerslev, J., Jakobsen, P., Avramis, V. I., Müller, H., Carlsen, N. T., & Schmiegelow, K. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.03148.x · Cited by 58
Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase*
Albertsen, B. K., Schrøder, H. D., Jakobsen, P., Avramis, V. I., Müller, H., Schmiegelow, K., & Carlsen, N. T. (2002) · Medical and Pediatric Oncology · doi:10.1002/mpo.10096 · Cited by 56
Rizzari, C., Valsecchi, M. G., Aricò, M., Conter, V., Testi, A. M., Barisone, E., Casale, F., Nigro, L. L., Rondelli, R., Basso, G., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1297 · Cited by 54
Self-citationTherapeutic drug monitoring of asparaginase in the ALL‐BFM 2000 protocol between 2000 and 2007
Schrey, D., Borghorst, S., Lanvers‐Kaminsky, C., Hempel, G., Gerß, J., Möricke, A., Schrappe, M., & Boos, J. (2010) · Pediatric Blood & Cancer · doi:10.1002/pbc.22417 · Cited by 52
Self-citationMonitoring of Erwinia asparaginase therapy in childhood ALL in the Nordic countries
Albertsen, B. K., Schrøder, H. D., Jakobsen, P., Müller, H., Carlsen, N. T., & Schmiegelow, K. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.01464.x · Cited by 47
Liang, D.-C., Hung, I., Yang, C.-P., Lin, K.-H., Chen, J.-S., Hsiao, T.-C., Chang, T.-T., Pui, C.-H., Lee, C., Lin, K.-S., et al. (1999) · Leukemia · doi:10.1038/sj.leu.2401260 · Cited by 45
Self-citationPinheiro, J. P. V., Wenner, K., Escherich, G., Lanvers‐Kaminsky, C., Würthwein, G., Janka‐Schaub, G. E., & Boos, J. (2005) · Pediatric Blood & Cancer · doi:10.1002/pbc.20406 · Cited by 41
Self-citationA population pharmacokinetic model for pegylated‐asparaginase in children
Hempel, G., Müller, H., Lanvers‐Kaminsky, C., Würthwein, G., Hoppe, A., & Boos, J. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07923.x · Cited by 37
Self-citationGoekbuget, N., Baumann, A., Beck, J., Boos, J., Brüggemann, M., Diedrich, H., Hüttmann, A., Leimer, L., Lipp, T., Naumann, R., et al. (2008) · Blood · doi:10.1182/blood.v112.11.302.302 · Cited by 27
Self-citationAvramis, V. I., Martín‐Aragón, S., Avramis, E. V., & Asselin, B. L. (2007) · PubMed · Cited by 26
Gadner, H., Masera, G., Schrappe, M., Eden, T. O. B., Benoît, Y., Harrison, C. J., Nachman, J. B., & Pui, C.-H. (2005) · Leukemia · doi:10.1038/sj.leu.2404016 · Cited by 21
Self-citationAlbertsen, B. K., Schmiegelow, K., Schrøder, H. D., Carlsen, N., Rosthøj, S., Avramis, V. I., & Jakobsen, P. (2002) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-002-0466-y · Cited by 20
Wenner, K., Pinheiro, J. P. V., Escherich, G., Wessalowski, R., Jorch, N., Wolff, J. E. A., Stehn, M., Kohlschütter, A., Boos, J., & Janka‐Schaub, G. E. (2005) · Klinische Pädiatrie · doi:10.1055/s-2005-872516 · Cited by 19
Self-citationHuguet, F., Raffoux, E., Thomas, X., Leguay, T., Chevallier, P., Escoffre‐Barbe, M., Reman, O., Caillot, D., Vey, N., Boissel, N., et al. (2006) · Blood · doi:10.1182/blood.v108.11.147.147 · Cited by 18
Kwok, C. S. N., Kham, S. K. Y., Ariffin, H., Lin, H. P., Quah, T. C., & Yeoh, A. E. J. (2005) · Pediatric Blood & Cancer · doi:10.1002/pbc.20684 · Cited by 17
Allas, S., Sahakian, P., Fichtner, I., & Abribat, T. (2009) · Blood · doi:10.1182/blood.v114.22.2033.2033 · Cited by 12
Storring, J. M., Brandwein, J. M., Gupta, V. K., Schuh, A. C., Schimmer, A. D., Yee, K. W. L., Wells, R. A., Lipton, J. H., Messner, H. A., Xu, W., et al. (2006) · Blood · doi:10.1182/blood.v108.11.1875.1875 · Cited by 9
Bertrand, Y., Thomas, X., Baruchel, A., Mazingue, F., Auvrignon, A., Corm, S., Dombret, H., Chevallier, P., Galambrun, C., Huguet, F., et al. (2008) · Blood · doi:10.1182/blood.v112.11.306.306 · Cited by 8
Self-citationOgawa, C., Ohara, A., Manabe, A., Hanada, R., Takahashi, H., Koh, K., Kajiwara, M., Maeda, M., Sugita, K., Kikuchi, A., et al. (2005) · Blood · doi:10.1182/blood.v106.11.878.878 · Cited by 7
Cited by
Sorted by citations
The emerging hallmarks of cancer metabolism
Pavlova, N. N., & Thompson, C. B. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.006 · Cited by 5,926
Modulation of oxidative stress as an anticancer strategy
Gorrini, C., Harris, I. S., & Mak, T. W. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4002 · Cited by 3,579
Inaba, H., Greaves, M., & Mullighan, C. G. (2013) · The Lancet · doi:10.1016/s0140-6736(12)62187-4 · Cited by 1,074
Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration
Pui, C., Yang, J. J. J., Hunger, S. P., Pieters, R., Schrappe, M., Biondi, A., Vora, A. J., Baruchel, A., Silverman, L. B., Schmiegelow, K., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.1636 · Cited by 1,016
Self-citationSurviving Stress: Modulation of ATF4-Mediated Stress Responses in Normal and Malignant Cells
Wortel, I. M. N., van der Meer, L. T., Kilberg, M. S., & van Leeuwen, F. N. (2017) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2017.07.003 · Cited by 630
Metadata
- Authors
- Pieters, R., Hunger, S. P., Boos, J., Rizzari, C., Silverman, L., Baruchel, A., Goekbuget, N., Schrappe, M., & Pui, C.
- Affiliations
- St. Jude Children's Research Hospital (US)
- Children's Hospital Colorado (US)
- University of Münster (DE)
- Azienda Ospedaliera San Gerardo (IT)
- Boston Children's Hospital (US)
- University Hospital Frankfurt (DE)
- University Hospital Schleswig-Holstein (DE)
- Corresponding author
- Pieters, Rob
- Pui, Ching‐Hon
- ORCID
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2010-09-07
- Volume
- 117
- Issue
- 2
- Pages
- 238-249
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- PMC
- PMC3000881
- OpenAlex
- W1965542498
- Cited by
- 569
- References
- 74
- Citations by year
- 2026: 17 · 2025: 25 · 2024: 35 · 2023: 38 · 2022: 49 · 2021: 53 · 2020: 56 · 2019: 43 · 2018: 41 · 2017: 41 · 2016: 39 · 2015: 37 · 2014: 42 · 2013: 28 · 2012: 18
- FWCI
- 2.45
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- Funders
- National Cancer Institute (CA21765, P01CA020180, P30CA021765)
- Topics
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Keywords
- L-asparaginase, acute lymphoblastic leukemia, PEG-asparaginase, pediatric leukemia, treatment protocols, dose optimization
- MeSH terms
- Asparaginase, Drug Combinations, Drug Hypersensitivity, Erwinia, Humans, Spironolactone, Sulfonamides, Drug Monitoring, Precursor Cell Lymphoblastic Leukemia-Lymphoma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
